Merck KGaA (FRA:MRK) received a €108.00 ($125.58) price target from equities research analysts at UBS Group in a note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price objective suggests a potential upside of 8.32% from the company’s current price.

MRK has been the subject of several other reports. Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Friday, March 8th. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, February 6th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday. Warburg Research set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Finally, Independent Research set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of €100.85 ($117.27).

MRK opened at €99.70 ($115.93) on Tuesday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What is the NASDAQ Stock Market?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.